Highlights of the Structure–Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)-Reference-Cited by-同舟云学术

Highlights of the Structure–Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)

Published:2018-04-13 Issue:9 Volume:61 Page:4052-4066
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wagner Rolf¹^ORCID,Randolph John T.¹^ORCID,Patel Sachin V.¹,Nelson Lissa¹,Matulenko Mark A.¹,Keddy Ryan¹,Pratt John K.¹^ORCID,Liu Dachun¹,Krueger A. Chris¹,Donner Pamela L.¹,Hutchinson Douglas K.¹,Flentge Charles¹,Betebenner David¹,Rockway Todd¹,Maring Clarence J.¹,Ng Teresa I.¹,Krishnan Preethi¹,Pilot-Matias Tami¹,Collins Christine¹,Panchal Neeta¹,Reisch Thomas¹,Dekhtyar Tatyana¹,Mondal Rubina¹,Stolarik DeAnne F.¹,Gao Yi¹,Gao Wenqing¹,Beno David A.¹,Kati Warren M.¹

Affiliation:

1. Global Pharmaceutical Research and Development, AbbVie, 1 North Waukegan Road, North Chicago, Illinois 60064, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00082

Reference95 articles.

1. Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome

2. An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis

3. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2